Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights
November 09, 2021 08:00 ET
|
Achilles Therapeutics PLC
- Oral Presentation at European Society for Gene and Cell Therapy (ESGCT) demonstrated ability to generate potent anti-cancer cell therapy candidates in multiple solid tumor types - - Society for...
Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Solid Tumor Types
October 22, 2021 07:30 ET
|
Achilles Therapeutics PLC
LONDON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics to join the Northern Alliance Advanced Therapy Treatment Centre consortium
October 12, 2021 08:00 ET
|
Achilles Therapeutics PLC
LONDON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics to Present at Upcoming Scientific Congresses
October 01, 2021 08:00 ET
|
Achilles Therapeutics PLC
LONDON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, will...
Achilles Therapeutics to Present at Upcoming Investor Conferences
September 02, 2021 08:30 ET
|
Achilles Therapeutics PLC
LONDON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Announces Grant of US and European Patents
August 25, 2021 08:00 ET
|
Achilles Therapeutics PLC
LONDON, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights
August 10, 2021 07:00 ET
|
Achilles Therapeutics PLC
– Presentations of translational science data at AACR and ASCO illustrate crucial path to potency assay – – Data from ten patients across CHIRON and THETIS studies anticipated in the fourth quarter...
Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer
July 01, 2021 08:00 ET
|
Achilles Therapeutics PLC
- Patient enrolled at the Moffitt Cancer Center, FL where Dr. Benjamin Creelan is the Principal Investigator - - CHIRON trial is enrolling up to 40 patients with advanced unresectable or metastatic...
Achilles Therapeutics Details Phase I/IIa Clinical Trial Design of CHIRON in Patients with Advanced Non-Small Cell Lung Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
June 04, 2021 09:00 ET
|
Achilles Therapeutics PLC
LONDON, United Kingdom, June 04, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid...
Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights
May 11, 2021 07:00 ET
|
Achilles Therapeutics PLC
- Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned - - Completed...